Ohio State University Comprehensive Cancer Center
Clinical trials sponsored by Ohio State University Comprehensive Cancer Center, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye on pancreatic cancer: Ultra-High resolution OCT could catch tumors at micrometer scale Results expected Sep 2026 (estimated)
- Soy pretzels vs. wheat pretzels: a surprising weapon against inflammation? Results expected Sep 2026 (estimated)
- Numbing cream may ease sting of cancer mapping shots Results expected Oct 2026 (estimated)
- New combo therapy aims to wipe out CLL cells in untreated patients Results expected Oct 2026 (estimated)
- Hunt for thyroid cancer genes begins in 1,200 families Results expected Dec 2026 (estimated)
-
Experimental combo for rare blood cancer shows promise but trial halted early
Disease control Stopped earlyThis early-phase trial tested a combination of two drugs—ruxolitinib and CPX-351—in 12 people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The goal was to find the best dose and see if the combo could shrink cancer. However, the study was stop…
Phase 1/2 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
A new approach to help homeless youth kick the habit?
Knowledge-focused Stopped earlyThis study aims to develop a smoking cessation program specifically designed for homeless youth. Researchers will interview and survey participants to understand their motivations for smoking and quitting. The goal is to build a program that addresses the unique challenges these …
Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC